R. Pragani

发表

Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery

Mindy I. Davis, A. Bartesaghi, S. Subramaniam, 2016, Cell.

Self-propagating reaction induced by ball milling in a mixture of Cu2O and Al powders

R. Pragani, L. Takács, A. Bakhshai, 2002 .

ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells

Mindy I. Davis, S. Gross, L. Dang, 2013 .

Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models*

Jennifer T. Fox, Mindy I. Davis, L. DeLucas, 2016, The Journal of Biological Chemistry.

Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.

M. Hall, J. Marugan, R. Pragani, 2021, Journal of medicinal chemistry.

A Homogeneous, High-Throughput Assay for Phosphatidylinositol 5-Phosphate 4-Kinase with a Novel, Rapid Substrate Preparation

Mindy I. Davis, L. Cantley, A. Simeonov, 2013, PloS one.

Total synthesis of the Bacteroides fragilis zwitterionic polysaccharide A1 repeating unit.

R. Pragani, P. Seeberger, 2011, Journal of the American Chemical Society.

Synthesis of conjugation-ready zwitterionic oligosaccharides by chemoselective thioglycoside activation

R. Pragani, P. Seeberger, C. Pereira, 2014 .

De novo synthesis of L-colitose and L-rhodinose building blocks.

R. Pragani, P. Seeberger, Oliviana Calin, 2012, The Journal of organic chemistry.

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Jiang Liu, R. Pazdur, R. Pragani, 2020, Clinical Cancer Research.

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays

Olivia W. Lee, Mindy I. Davis, D. Urban, 2017, Scientific Reports.

Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1*

Mindy I. Davis, S. Gross, B. Delabarre, 2014, The Journal of Biological Chemistry.

Mutant Isocitrate Dehydrogenase IDH 1 Characterization of a Potent Inhibitor of Biochemical , Cellular , and Biophysical Molecular Bases of Disease

S. Gross, B. Delabarre, L. Dang, 2014 .

Structure activity relationships of human galactokinase inhibitors.

Min Shen, Manshu Tang, Kent Lai, 2015, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.

Mindy I. Davis, D. Urban, Adam Yasgar, 2021, Journal of medicinal chemistry.

Studies on the synthesis of durhamycin A: stereoselective synthesis of a model aglycone.

R. Pragani, W. Roush, 2008, Organic letters.

Multimodal action of KRP203 on phosphoinositide kinases in vitro and in cells.

Mindy I. Davis, A. Simeonov, R. Pragani, 2023, Biochemical and biophysical research communications.

FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer.

R. Pazdur, R. Pragani, H. Gittleman, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion.

R. Pragani, M. Boxer, A. Sasaki, 2024, Biochemical and biophysical research communications.